Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Calin Arimie
OpenAlex ID:
A5012773115
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2024
·
Marc Ferrante
, Marc Ferrante
, et al.
·
The Lancet
·
120
PDF
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection
2023
·
Matthew D. Sims
, Sahil Khanna
, et al.
·
JAMA Network Open
·
83
PDF
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
2024
·
Colleen S. Kraft
, Matthew Sims
, et al.
·
Infectious Diseases and Therapy
·
9
PDF
Histologic and combined histologic–endoscopic outcomes with mirikizumab in Crohn’s disease: VIVID-1 trial results
2026
·
Vipul Jairath
, Fernando Magro
, et al.
·
Journal of Crohn s and Colitis
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
2024
·
Colleen S. Kraft
, Matthew Sims
, et al.
·
Infectious Diseases and Therapy
PDF
Show more works
View as search
Works count:
5
Citation count:
211
H-index:
3
I10-index:
2
Year
Topic
Type
